COMMUNIQUÉS West-GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
22/07/2026
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
22/07/2026
LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
uniQure to Announce Second Quarter 2026 Financial Results
22/07/2026
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing [...]
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
22/07/2026
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema Explains the scientific foundation for targeting the bradykinin [...]
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
22/07/2026
Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and [...]
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, [...]
Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
22/07/2026
New AMA Category III codes, effective July 1, 2026, support the development of future reimbursement pathways for temporary transvenous diaphragm neurostimulation EXTON, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Lungpacer [...]
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
22/07/2026
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) [...]
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
22/07/2026
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A [...]
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close [...]
Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
22/07/2026
Sales rise 29.3% and EBITDA grows 68.1%; newly appointed Board of Directors to lead the next phase of aerospace and defense growth Fiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of [...]
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
22/07/2026
Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose- [...]
ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer
22/07/2026
Brings nearly three decades of clinical, translational and biotechnology experience, strengthening ReBio's leadership team as it prepares to advance RBP-01 into the clinic RBP-01 targets primary uveal melanoma, the most [...]
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026
22/07/2026
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 Halle (Saale) / Munich, Germany, July 22 , 2026 - Vivoryon [...]
GlycoReset Supplement Facts Released: Consumer Safety Report Details New Analysis About Glyco Reset Ingredients & Side Effects Risk
22/07/2026
Berberine, Ceylon Cinnamon, Gymnema Sylvestre, Chromium Picolinate and Four More Compounds in the Glyco Reset Drops Formula Wilmington, DE, July 21, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by [...]
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
22/07/2026
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
22/07/2026
PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus [...]
Ipsen finalise l'acquisition de Memo Therapeutics AG, ajoutant un actif premier de sa classe au portefeuille de maladies rares d'Ipsen
22/07/2026
PARIS, FRANCE, 22 JUILLET 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd'hui avoir finalisé l'acquisition de Memo Therapeutics AG - une société de biotechnologie en phase avancée de développement - portant [...]

Pages